Amgen's earnings call for Q3 2006 indicates strong performance and growth, with revenue and EPS growth exceeding expectations, and raised EPS guidance for the full year. Notable achievements include successful product launches, including Vectibix, and strategic acquisitions like Avidia. Additionally, the company's focus on R&D is significant, with multiple trials initiated and expansion plans in key areas, suggesting a robust pipeline. However, the market may focus on litigation and competitive pressures from Roche's peg-EPO, though Amgen's confidence in its legal stance and product strategy could mitigate concerns. Overall, the tone reflects a favorable outlook, suggesting potential positive short-term stock movement.

[1]